Eli Lilly and Company (LLY)vsSanara Medtech Inc (SMTI)
LLY
Eli Lilly and Company
$1,289.42
+0.50%
HEALTHCARE · Cap: $1.12T
SMTI
Sanara Medtech Inc
$32.88
+0.12%
HEALTHCARE · Cap: $303.39M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 72446% more annual revenue ($79.67B vs $109.81M). LLY leads profitability with a 33.5% profit margin vs -29.1%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
SMTI
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+58.3%
Fair Value
$46.57
Current Price
$32.88
$13.69 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
No standout strengths identified
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 33.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.9% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : SMTI
SMTI has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : SMTI
The primary concerns for SMTI are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 6.11 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while SMTI is a turnaround play — different risk/reward profiles.
SMTI carries more volatility with a beta of 1.19 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 25/100), backed by strong 33.5% margins and 47.7% revenue growth. SMTI offers better value entry with a 58.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sanara Medtech Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Sanara MedTech Inc. develops, markets and distributes skin and wound care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company is headquartered in Fort Worth, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?